Background Major risk factors for accelerated allograft arteriosclerosis include humoral and cellular immune response, hyperlipidemia, and viral infections. We demonstrated earlier that rat cytomegalovirus (RCMV) infection doubles smooth muscle cell proliferation and intimal thickening of rat aortic allografts. In this study, the effects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) on RCMV-enhanced rat allograft arteriosclerosis are investigated.
Background Major risk factors for accelerated allograft arteriosclerosis include humoral and cellular immune response, hyperlipidemia, and viral infections. We demonstrated earlier that rat cytomegalovirus (RCMV) infection doubles smooth muscle cell proliferation and intimal thickening of rat aortic allografts. In this study, the effects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) on RCMV-enhanced rat allograft arteriosclerosis are investigated.
Methods and Results Aortic allografts from the DA to the WF rat strain were used. The recipients were inoculated with 10' plaque-forming units of RCMV 1 day after transplantation. Two groups of RCMV-infected rats were treated with DHPG with an initial dose of 20 mg/kg IP and a maintenance dose of 10 mg/kg IP twice a day for a period of 14 days. In the DHPG prophylaxis group (n=22), the drug administration started 1 day before infection, and in the DHPG treatment group (n= 17), 7 days after infection. One group of infected rats was left untreated (n=21). The grafts were removed 7 and 14 days and 1, 3, and 6 months after transplantation. In the DHPG prophylaxis group, no virus could be recovered by plaque assays. In the treatment group, 50% of rats were virus-positive at 1 month and 40% at 3 months. DHPG prophylaxis prevented the infiltration of inflammatory cells and their proliferation in the adventitia of RCMV-infected recipients (P<.01), with a 60% reduction in the interleukin-2 receptor expression (P<.05) and a 30% decrease in major histocompatibility complex class II expression (P=NS). DHPG prophylaxis did not significantly alter the levels of insulin-like growth factor-1, epidermal growth factor, platelet-derived growth factor-BB, transforming growth factor-13l, acidic fibroblast growth factor, and basic fibroblast growth factor messages in the allograft vascular wall. Early media necrosis was reduced. Arteriosclerotic alterations and proliferation of smooth muscle cells were both reduced 50% to 70% by DHPG prophylaxis (P<.05 at 3 months). The responses in the DHPG treatment group were quite similar but less impressive and statistically nonsignificant.
Conclusions We consider it likely that DHPG inhibits arteriosclerotic alterations primarily by reducing the infectious virus and thereby the inflammatory response in the allograft vascular wall; another possibility is a direct antiproliferative effect on smooth muscle cell replication. A dosedependent inhibitory effect of DHPG on smooth muscle cell replication was recorded in an in vitro study. (Circulation. 1994; 90:1969 -1978 Key Words * transplantation * ganciclovir * smooth muscle cells * growth substances * arterioscierosi M ajor risk factors for accelerated allograft arteriosclerosis, ie, chronic rejection, in heart transplant recipients include humoral and cellular immune responses,1-4 hyperlipidemia,5-7 and viral infections.8-1' We demonstrated with our rat aortic allograft model12 that rat cytomegalovirus (RCMV) infection doubles allograft arteriosclerosis. 13 The drug of choice for the treatment of CMV infection is 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG; ganciclovir).14 DHPG is an acyclic analogue of the natural 2'-deoxyguanosine. '5 The mechanism of action of this drug depends on the formation of a a direct antiproliferative effect on the secretory phenotype of vascular smooth muscle cells.
Methods Experimental Protocol
Recipients of aortic allografts were infected intraperitoneally with RCMV 1 day after transplantation and were given DHPG either from day 0 (DHPG prophylaxis group) or day 7 (DHPG treatment group) for a period of 14 days or were left untreated and used as controls. The grafts were removed at 7 and 14 days and at 1, 3, and 6 months, and there were (5, 5, 4, 4, 3) rats in the RCMV-infected untreated group, (5, 4, 3, 6, 4) 
Plaque Assays
The potency testing of RCMV was done by plaque assays as described.27 Confluent rat embryo fibroblast monolayers were washed with Hanks' balanced salt solution (lx) (Gibco), infected with appropriate virus dilution and incubated at +37°C in a 5% CO2 incubator for 60 minutes. After incubation, the infected cells were overlaid with 1 mL basal medium (BME) (Eagle) (Gibco) supplemented with glutamine, penicillin, streptomycin (as above), and 5% FCS (Sera-Lab) at a final concentration of 0.25% Agarose (Sigma Chemical Co). After 7 days, the cells were fixed in 10% formalin overnight; then the solid base layer was removed, and the cell monolayers were stained with 1% aqueous crystal violet (Merck). The plaques were counted by light microscopy.
Quantification of infectious RCMV from the biopsies of salivary glands, liver, and spleen was done by the plaque assay.27 Briefly, biopsies were taken aseptically in MEM with 2% FCS (supplemented as above) and stored at -70°C. The organs were homogenized in a tissue grinder and suspended in MEM with 2% FCS (as above), and 10-fold dilutions of 10% homogenates (wt/vol) were inoculated on confluent rat embryo fibroblast monolayers. After an incubation of 7 days, the number of plaques was monitored microscopically.
ELISA
ELISA was carried out on polyvinyl chloride plates coated with cellular antigens obtained from RCMV-infected rat fibroblasts. Mock antigen was used for negative controls. The RCMV antigen was prepared by the glycine-buffered extraction method. 28 The polyvinyl chloride ELISA plates were coated with RCMV antigen 10 ,gg/mL in carbonate buffer, pH 9.6, at +4°C overnight before incubation. After the plates were washed with the buffer, serum samples at appropriate dilutions were added into the wells and incubated at +37°C for 60 minutes. After the wash with buffer, peroxidase-conjugated goat anti-rat IgG (H+L) (Cappel Laboratories) was added at a dilution of 1:2000 in buffer with 0.5% bovine serum albumin. After washing, OPD substrate citrate phosphate buffer (orthophenylenediamine; Sigma P-3888) was added and incubated for 15 minutes. To stop the color reaction, 2 mol/L H2S04 was added, and the intensity was determined by Multiscan ELISA reader at 492 nm. The values are expressed as the difference of extinction between positive and negative antigen (AE). AEs200 is assumed to be negative. DHPG DHPG (ganciclovir; Cymevene 500 mg; Syntex) was dissolved in 100 mL of 0.9% NaCl at a final concentration of S mg/mL. DHPG was administrated intraperitoneally at an initial dose of 20 mg/kg and a maintenance dose of 10 mg/kg twice a day for 14 days.
Histology
The grafts were fixed in 10% phosphate-buffered formalin, embedded in paraffin, and examined histologically after sectioning and staining with Mayer's hematoxylin-eosin. Cross sections were prepared for evaluation of circular changes in the graft. No difference was observed whether or not in situ fixation was performed. Nontransplanted DA rat thoracic aortas were used as normal controls.
Morphometry
Histological changes were quantified according to standard morphometric principles29 and are expressed as the mean number of points falling over a given anatomic area using straight, cross-sectional lines and a 0.02-mm grid and are given as point score units (PSU). The number of cell nuclei in the adventitia, media, and intima and intimal thickness were evaluated. Final scores were given as mean±SEM.
Autoradiography
All rats received 300 ,Ci of (methyl-3H)thymidine ('H-TdR; Amersham International plc) IV 3 hours before they were killed. Histology was processed from paraffin cross sections, and emulsion film autoradiography ( 
Smooth Muscle Cell Culture
Smooth muscle cells were isolated from 9-to 11-day-old DA rat thoracic aortas.32 The aortas were opened longitudinally, and the intimal layer was gently scraped off; the media and the adventitia were carefully separated and sliced into small pieces. The different layers were digested with 0.1% collagenase and 0.02% DNAse in PBS at +37°C for 1 to 2 hours. Isolated smooth muscle cells from the media were centrifuged, suspended in culture medium (as above), seeded in plastic flasks, and incubated in a 5% CO2 incubator at +37°C. Passages 2 through 4 were used for investigation.
Smooth muscle cells were seeded in 96-microtiter wells (5000 cells/well) in Dulbecco's MEM (Flow Laboratories) supplemented with 10% FCS (Sera-Lab), 2 ,mol/mL glutamine, and 1000 ,g/mL streptomycin/10 000 U/mL penicillin.
DHPG was added at concentrations of 0, 1, 10, 100, and 1000 ,g/mL. The cells were exposed daily to 1 ,uCi/mL of 3H-TdR for 24 hours to quantify DNA synthesis. After In nontreated RCMV-infected rats (Table 1) , infectious virus could usually be recovered from the biopsies of liver/spleen 7 days after transplantation but not thereafter (acute infection). In contrast, plaque assays from the salivary glands did not yield infectious virus until 1 and 3 months after inoculation (chronic infection). Six months after transplantation, no infectious virus could be demonstrated from organ biopsies (latent infection), and the rats were assumed to be latently infected.
In the DHPG prophylaxis group, no infectious virus could be isolated by plaque assays from the organ biopsies during the whole observation time. In the DHPG treatment group, the virus could be isolated only from salivary glands in 50% (3/6) of the rats 1 month after infection and in 40% (2/5) of the rats 3 months after infection (Table 1) .
Effect of DHPG on the Humoral Immune Response to RCMV Infection The RCMV-IgG antibody level was measured by ELISA 3 and 6 months after transplantation. High-level antibody formation to RCMV was observed in nontreated RCMV-infected allografts, as shown in Table 2 . In the DHPG prophylaxis group, antibody formation was below the threshold level. In the DHPG treatment group, low humoral immune response to RCMV was detected in 67% and 75% of the rats at 3 and 6 months. respectively.
Effect of DHPG on RCMV-Enhanced Allograft Arteriosclerosis
Aortic allografts were transplanted from the DA to the WF rat strain and harvested 7 and 14 days and 1, 3, and 6 months after transplantation. Histological changes were quantified by morphometry29 and are given as PSU±SEM.
Adventitia
There were only a few cells, mainly fibroblasts, in the adventitia of nontransplanted DA aortas (0.5±0.5 PSU, ±SD). In RCMV-infected allografts, an intense adventitial inflammatory response to 11.6±1.5 PSU occurred 7 days after transplantation. The inflammatory response was increased to 15.6±1.5 PSU 1 month after transplantation, after which it declined.13 The early inflammatory response in RCMV-infected allografts was inhibited by DHPG prophylaxis to the level of 6.1±0.2 PSU (P<.01) at 7 days (Fig la) . DHPG treatment had no influence on the early inflammatory response (Fig 2a) . The peak inflammatory response of both DHPG groups occurred at 1 month but was reduced by 30% compared with RCMV-infected allografts (P<.05 for DHPG prophylaxis). Thereafter, the number of adventitial cell nuclei in the DHPG groups showed the same decline as in the control group. 
Media
The number of cell nuclei in the media of nontransplanted DA aortas was 3.1±0.1 PSU (±SD). In RCMVinfected allografts, media necrosis with loss of media nuclei developed after 1 month, declining to 0.6±0.2 PSU 3 months after transplantation.13 In the DPHG prophylaxis (Fig lb) and treatment (Fig 2b) groups, the number of media cells remained approximately within the normal variation up to 1 month compared with RCMV-infected allografts (P<.05 for the DHPG-prophylaxis group). In the prophylaxis and treatment groups, media necrosis was first observed at 3 months, reaching 0.5±0.3 PSU in the prophylaxis and 0.3±0.1 PSU in the treatment group at 6 months after transplantation.
Intima
The most important effects of DHPG were observed in the intima and are depicted in Figs lc, ld, 2c, and 2d. Intimal cells. The luminal surface of nontransplanted DA aortic wall is normally lined by an endothelial cell monolayer, ie, on average 0.9±0.2 PSU (+SD) nuclei only. In RCMV-infected allografts, the number of intimal nuclei increased to 1.6±0.1 PSU 7 days after transplantation. It reached a peak of 3.6+0.7 PSU at 1 month, remained unchanged at 3 months, and declined aortic cross section ± SEM. In normal aortas, no nuclear labeling is detected after 3H-TdR pulse.
Adventitia
In RCMV-infected allografts, the peak in cell proliferation occurred 7 days after transplantation, reaching 227±21 labeled nuclei per aortic cross section. The proliferative response declined to 115+24 labeled nuclei at 1 month, after which only low-level proliferative response was observed.13 In the DHPG prophylaxis group compared with RCMV-infected nontreated allografts (Fig 3a) , the early proliferative peak of inflammatory cells on day 7 was reduced to 91±20 labeled nuclei (P<.05), remained at the same level up to 1 month, and declined to the level observed in RCMVinfected allografts at 3 months. The proliferative response in the DHPG treatment group was less affected (Fig 4a) .
Media
In RCMV-infected allografts, a gradual proliferative response occurred, increasing to 14±4 labeled nuclei at 7 days, 22±2 labeled nuclei at 14 days, and 19±7 labeled nuclei at 1 month and declining thereafter. 13 In the DHPG prophylaxis group (Fig 3b) , the early proliferative response of media cells was inhibited to half of that observed in RCMV-infected allografts, reaching 6±3 labeled nuclei at 7 days (P<.05) and 11±2 labeled nuclei at 14 days (P<.05). The same degree of inhibition was also observed in the DHPG treatment group, with Smooth muscle cells were isolated from 9-to 11-day-old DA rat thoracic aortas and seeded in 96-microtiter wells. The cells were exposed daily to 1 ,uCi/mL of 3H-TdR for 24 hours to quantify DNA synthesis. The 3H-TdR incorporation is given as counts per minute (cpm). The values represent the mean ±SEM of 6 wells in the second experiment. *P< .0001 on day 4 by the Kruskal-Wallis and the Dunn tests, when 100 .tg/mL and 1000 j.g/mL are compared with control media. Note that the inhibitory effect of DHPG proved not to be reversible on removal of the drug and replacement of fresh conditioned medium on day 4. Under light microscopy, the smooth muscle cell viability was good. This, however, does not exclude the fact that concentrations of 100 and 1000 ,ug/mL might be toxic. Fig 1. IGF indicates insulin-like growth factor; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; TGF, transforming growth factor; aFGF, acidic fibroblastic growth factor; and bFGF, basic fibroblastic growth factor.
11±4 labeled nuclei 14 days (P<.05) after transplantation (Fig 4b) . Intima In RCMV-infected allografts, proliferating intimal cells with 13±2 labeled nuclei were first observed at 7 days after transplantation. The proliferation rate reached a peak of 20±3 labeled nuclei at 1 month. After 3 months, the proliferative response declined rapidly to 5±2 proliferating cells. 13 In the DHPG prophylaxis group (Fig 3c) 
IL-2R
In RCMV-infected allografts, there were 29±9 IL-2R-expressing cells 7 days and 299±46 IL-2R-expressing cells 1 month after transplantation. 35 There was a significant reduction (P<.05) in the number of IL-2R-positive cells in the DHPG prophylaxis group at 1 month (Fig Sa) . In the DHPG treatment group, no significant reduction was observed (Fig Sb) .
MHC Class II
In RCMV-infected allografts, a prominent class II expression with a score of 4.5 ±0.3 was seen 7 days after transplantation and remained at the same level at 1 month.35 In the DHPG prophylaxis group (Fig Sc) , the expression of MHC class II molecule was slightly reduced to 3.2±0.2 at 1 month (P=NS), whereas in the DHPG treatment group (Fig 5d) , MHC class II was moderately present during the whole observation time (P=NS). I. Furthermore, studies with balloon catheter denudation suggest that bFGF may be a key mitogen for the initiation of smooth muscle cell replication, but it is not important in the continuation of intimal smooth muscle cell replication.42 In our study, DHPG prophylaxis did not alter the (elevated) expression levels of these mitogens, suggesting that other pathways for the regulation of smooth muscle cell replication exist.
The distinct inhibitory response by DHPG therapy both in smooth muscle cell proliferation in the allograft media and intima and in the generation of arteriosclerotic changes in the allograft suggests that the inhibitory effect of DHPG on virus infection-enhanced allograft arteriosclerosis is not linked only to an inhibition of the viral replication but that additional pathways may also 
Study Limitations
There are certain limitations to our study. Our rat aortic allograft model may not be entirely analogous to the coronary wall in human cardiac allografts. However, rat aortic allografts developed arteriosclerotic alterations that are virtually indistinguishable from those observed during chronic cardiac rejection in humans. With this aortic allograft model, we gain insight into the pathophysiological mechanisms of chronic rejection in the vascular wall itself, whereas in a heart transplant model, the coronary arteries should be dissected free from the surrounding tissue to obtain growth factors and cytokines from the vascular wall of the allografts.
Although the natural history of rat CMV infection is quite similar to that seen in human CMV infection, there are some differences. The incubation time for RCMV infection is only 7 days, whereas in humans, most CMV infections occur within 60± 60 days after cardiac transplantation. This implies that the optimal duration and the timing needed for DHPG prophylaxis to prevent the development of CMV-enhanced allograft arteriosclerosis in humans will be difficult to determine on the basis of our experimental data. Unfortunately, only a limited number of growth factors and cytokines were investigated in this study. DHPG prophylaxis prevented the prominent inflammatory response and immune activation in the vascular wall of RCMV-infected allografts. No inhibitory effect was seen in growth factor messages. This finding suggests that the growth factors, previously shown to be elevated in the vascular wall during unmodified and RCMV-enhanced allograft arteriosclerosis, are not the only regulatory molecules for smooth muscle cell replication.
Our observations suggest that DHPG may be useful in clinical prophylaxis of CMV infection in heart transplant patients, not only as it decreases morbidity in acute infection, but also as it inhibits accelerated allograft arteriosclerosis. A randomized doubled-blind multicenter clinical trial should be conducted to validate these experimental observations in humans.
Conclusions
Our study demonstrates that DHPG prophylaxis entirely abolishes the accelerating effect of RCMV infection on allograft arteriosclerosis in the rat. Furthermore, early prophylaxis of RCMV infection with DHPG prevents the development of viral infection. The effect of DHPG treatment in the inhibition of virus infection and virus-enhanced arteriosclerotic process was less prominent compared with DHPG prophylaxis. These results suggest that DHPG might be useful in clinical prophylaxis of CMV infection among heart transplant recipients, not only as it decreases morbidity in acute infection but also as it inhibits accelerated allograft arteriosclerosis.
